These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 37426321)

  • 1. Stereotactic body radiotherapy combined with sintilimab in patients with recurrent or oligometastatic hepatocellular carcinoma: A phase II clinical trial.
    Chen YX; Yang P; Du SS; Zhuang Y; Huang C; Hu Y; Zhu WC; Yu YY; Liu TS; Zeng ZC
    World J Gastroenterol; 2023 Jun; 29(24):3871-3882. PubMed ID: 37426321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients.
    Collen C; Christian N; Schallier D; Meysman M; Duchateau M; Storme G; De Ridder M
    Ann Oncol; 2014 Oct; 25(10):1954-1959. PubMed ID: 25114022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
    Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
    Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic body radiotherapy for recurrent and oligometastatic soft tissue sarcoma.
    Feng XY; Li J; Li AM; Jing SH; Zhu XX; Wang Z
    World J Surg Oncol; 2022 Sep; 20(1):322. PubMed ID: 36171617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereotactic body radiotherapy delivered with IMRT for oligometastatic regional lymph node metastases in hepatocellular carcinoma: a single-institutional study.
    Matoba M; Tsuchiya H; Kondo T; Ota K
    J Radiat Res; 2020 Sep; 61(5):776-783. PubMed ID: 32845298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT).
    Scorsetti M; Comito T; Cozzi L; Clerici E; Tozzi A; Franzese C; Navarria P; Fogliata A; Tomatis S; D'Agostino G; Iftode C; Mancosu P; Ceriani R; Torzilli G
    J Cancer Res Clin Oncol; 2015 Jul; 141(7):1301-9. PubMed ID: 25644863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Multi-Institutional Retrospective Study of Repeated Stereotactic Body Radiation Therapy for Intrahepatic Recurrent Hepatocellular Carcinoma.
    Kimura T; Takeda A; Tsurugai Y; Kawano R; Doi Y; Oku Y; Hioki K; Miura H; Nagata Y
    Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1265-1275. PubMed ID: 32712256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic outcome and related predictors of stereotactic body radiotherapy for small liver-confined HCC: a systematic review and meta-analysis of observational studies.
    Long Y; Liang Y; Li S; Guo J; Wang Y; Luo Y; Wu Y
    Radiat Oncol; 2021 Apr; 16(1):68. PubMed ID: 33832536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 2 multicenter study of stereotactic body radiotherapy for hepatocellular carcinoma: Safety and efficacy.
    Jang WI; Bae SH; Kim MS; Han CJ; Park SC; Kim SB; Cho EH; Choi CW; Kim KS; Hwang S; Kim JH; Chang AR; Park Y; Kim ES; Kim WC; Jo S; Park HJ
    Cancer; 2020 Jan; 126(2):363-372. PubMed ID: 31747476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study.
    Masini C; Iotti C; De Giorgi U; Bellia RS; Buti S; Salaroli F; Zampiva I; Mazzarotto R; Mucciarini C; Vitale MG; Bruni A; Lohr F; Procopio G; Caffo O; Nole F; Morelli F; Baier S; Buttigliero C; Ciammella P; Timon G; Fantinel E; Carlinfante G; Berselli A; Pinto C
    Eur Urol; 2022 Mar; 81(3):274-282. PubMed ID: 34602312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical study.
    Li D; Xu L; Ji J; Bao D; Hu J; Qian Y; Zhou Y; Chen Z; Li D; Li X; Zhang X; Wang H; Yi C; Shi M; Pang Y; Liu S; Xu X
    Front Immunol; 2022; 13():944062. PubMed ID: 36091003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereotactic body radiotherapy for primary hepatocellular carcinoma.
    Andolino DL; Johnson CS; Maluccio M; Kwo P; Tector AJ; Zook J; Johnstone PA; Cardenes HR
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e447-53. PubMed ID: 21645977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 2 Study of Stereotactic Body Radiation Therapy for Patients with Oligometastatic Esophageal Squamous Cell Carcinoma.
    Liu Q; Zhu Z; Chen Y; Deng J; Ai D; Liu Q; Wang S; Wu S; Chen J; Zhao K
    Int J Radiat Oncol Biol Phys; 2020 Nov; 108(3):707-715. PubMed ID: 32417405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic Body Radiotherapy for Large Unresectable Hepatocellular Carcinomas - A Single Institution Phase II Study.
    Beaton L; Dunne EM; Yeung R; Rackley T; Weber B; Mar C; Yong-Hing CJ; Yoshida EM; DeVries K; Lee R; Duzenli C; Loewen SK; Liu M; Schellenberg D; Ma R
    Clin Oncol (R Coll Radiol); 2020 Jul; 32(7):423-432. PubMed ID: 32093876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Local control by salvage stereotactic body radiotherapy for recurrent/residual hepatocellular carcinoma after other local therapies.
    Kibe Y; Takeda A; Tsurugai Y; Eriguchi T
    Acta Oncol; 2020 Aug; 59(8):888-894. PubMed ID: 32216593
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm.
    Su TS; Lu HZ; Cheng T; Zhou Y; Huang Y; Gao YC; Tang MY; Jiang HY; Lian ZP; Hou EC; Liang P
    BMC Cancer; 2016 Nov; 16(1):834. PubMed ID: 27809890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereotactic body radiotherapy in hepatocellular carcinoma: patient selection and predictors of outcome and toxicity.
    Loi M; Comito T; Franzese C; Dominici L; Lo Faro L; Clerici E; Franceschini D; Mancosu P; Reggiori G; Gallo P; Badalamenti M; Scorsetti M
    J Cancer Res Clin Oncol; 2021 Mar; 147(3):927-936. PubMed ID: 32945972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of SBRT combined with sintilimab and IBI305 in patients with advanced HCC and previously failed immunotherapy: study protocol of a phase 2 clinical trial.
    Zhang J; Yang Y; Wu Z; Zhang S; Lin Z; Liu H; Hu J; Zhang T; Tang J; Xue J
    BMJ Open; 2024 Jun; 14(6):e077903. PubMed ID: 38858156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic Body Radiotherapy and Liver Transplant for Liver Cancer: A Nonrandomized Controlled Trial.
    Lee VH; Vardhanabhuti V; Wong TC; Lam KO; Choi HC; Chiu KW; Ho PP; Leung DK; Szeto MH; Choi KF; Chan SC; Leung TW; Khong PL; Lo CM
    JAMA Netw Open; 2024 Jun; 7(6):e2415998. PubMed ID: 38857045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sintilimab, stereotactic body radiotherapy and granulocyte-macrophage colony stimulating factor as second-line therapy for advanced non-small cell lung cancer: safety run-in results of a multicenter, single-arm, phase II trial.
    Ni J; Zhou Y; Wu L; Ai X; Dong X; Chu Q; Han C; Wang X; Zhu Z
    Radiat Oncol; 2021 Sep; 16(1):177. PubMed ID: 34526044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.